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Molecular imaging techniques such as single photon emission computed tomography (SPECT) or positron emission tomography
are promising tools for noninvasive diagnosis of acute allograft rejection (AR). Given the importance of renal transplantation and
the limitation of available donors, detailed analysis of factors that affect transplant survival is important. Episodes of acute allograft
rejection are a negative prognostic factor for long-term graft survival. Invasive core needle biopsies are still the “goldstandard” in
rejection diagnostics. Nevertheless, they are cumbersome to the patient and carry the risk of significant graft injury. Notably, they
cannot be performed on patients taking anticoagulant drugs. Therefore, a noninvasive tool assessing the whole organ for specific
and fast detection of acute allograft rejection is desirable. We herein review SPECT- and PET-based approaches for noninvasive
molecular imaging-based diagnostics of acute transplant rejection.
1. Introduction
Noninvasive imaging techniques formedical diagnosis allow-
ing visualization of specific biological processes have made
tremendous progress in the last decades. One major issue
focused on the advances in sensitivity and specificity but also
on compatibility, accessibility, and affordability.
Scintigraphy, single-photon emission computed tomog-
raphy (SPECT), and positron emission tomography (PET)
are imaging procedures based on the detection of internal
radiation (mostly intravenous injection of a radioactive
tracer), where gamma rays emitted by tracers containing
radionuclides (directly in gamma scintigraphy and SPECT
or indirectly (annihilation) in PET) are captured via an
external detector system (gamma camera). Nuclear imaging
has the benefits of high intrinsic sensitivity, recognising
targets present in a very low concentration, exceptional
penetration of tissues, whole-body visualisation, and a large
range of available, clinically tested tracers and consequently a
high specificity [1, 2].
While planar scintigraphy produces two-dimensional
pictures, SPECT and PET offer the possibility to generate
three-dimensional images allowing higher resolution and
therefore better monitoring of the deposition and clearance
of the employed tracers. The difference of SPECT and PET
lies in the detection procedure, resolution, and utilized
radionuclides. The spatial resolution is restricted to 3–5mm
in PET and 8–10mm in SPECT; however, detection of the
contrast agent is even possible in the nano- and picomolar
range [3]. Although PET offers better quantification and a
2- to 3-fold superior sensitivity than SPECT, the latter still
reflects the most commonly used imaging technology due
to cost-effectiveness, availability, and existence of a broader
array of adequate radionuclides [4]. Both imaging techniques
generate functional images of metabolic processes and not
morphological visualisation. Therefore, these modalities are
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utilized for evaluation of the function of the examined
organ and illustration of molecular and cellular events
like apoptosis, inflammation, infection, change in pH, and
metabolism [5]. This review focuses on the principles of
SPECT and PET and their field of preclinical and clinical
application and gives an overview of their potential mode
of operation diagnosis of acute (renal) allograft rejection
(AR).
2. Radiopharmaceuticals
In order to receive expedient information about the biological
process of interest, the applied radiotracers have to fulfil a
variation of features. First, the utilized contrast agent needs
to bind sufficiently to the target of interest, delivering a
clear signal greater than the background noise of the sur-
rounding tissue (good signal-to-noise ratio) [5]. Appropriate
tracers have a great binding specificity for molecular targets,
upregulated under specific pathologic settings, permitting
comparison to the physiological state. Further, a good tracer
allows visualisation in very low concentration and of low
concentrated targets, limiting its side effects. The more
specific the marker for a condition or a disease is, the
more precise the information obtained is. Fast clearance
of the used radionuclides is also an aspect that needs to
be taken into consideration. Otherwise, distinction between
specific and unspecific signal is not possible [5]. Distinct
radiopharmaceuticals have been developed for SPECT and
PET, nicely overviewed by Signore and Fani [2, 6].
In PET, the predominant radionuclide used for tracers
depicts 18F, but othermarkers to visualize biological processes
like 11C, 13N, 15O, 68Ga, 64Cu, 60Cu, 86Y, 89Zr, and 124I
have been developed. 18F-based tracers utilized in PET
directly incorporate the radionuclide into the biomolecule via
substitution making it almost undistinguishable from their
nonradioactive analogs by displaying the same characteristics
[7]. Depending on the target of interest (e.g., proteins and
cellular processes), a suitable compound (peptide, proteins,
antibodies, or smallmolecules), serving as basis for the tracer,
needs to be selected [8]. Not only should the duration of the
process of interest correspond to the half-life of the chosen
radionuclide but also the emitted energy of the positrons
needs to be considered for the spatial resolution (low energy
and better spatial resolution) [8]. The radiopharmaceutical
most commonly used in clinics is 18F-FDG (with a com-
parable metabolism to normal glucose but trapping of 18F-
FDG in the cell) for determination of metabolic activity,
inflammatory sites, and oncologic analysis.
99mTc, 111In, 67Ga, and 123I depict the deployed markers
for SPECT imaging. Among these 99mTc represents the
radionuclide with the largest area of application due to its
optimal decay characteristics, easy production, and availabil-
ity [7]. Compared to PET tracers, the generally longer half-
lives of these SPECT radionuclides constitute an advantage
correlating better with the half-lives of biological processes.
In addition, these radiotracers are generally available. Fur-
thermore, 99mTc-based tracers are easy to produce by a
generator and do not need a nearby medical cyclotron [9] in
contrast to rather short-lived unstable PET tracers. However,
SPECT tracers also show some disadvantages. Incorporation
of 99mTc, for example, into a molecule is more complex than
the substitution of 18F in PET, involving chelating moieties
and leading to possible steric hindrance [7].Therefore, 99mTc-
based labelling is not suitable for imaging every process. It has
been employed for visualisation of bone and joint infections,
while 67Ga was successfully applied in tumor imaging [10].
For identification of hypoxic areas different tracers usable
for standard gamma cameras have been developed such as
123I-labelled iodoazomycin arabinoside and different 99mTc-
based compounds [11–13].
3. Labelling of Intracellular Targets
Gallagher et al. reported already in 1978 the potential of
18F-FDG for scintigraphic detection of glucose metabolism
[14]. The cellular uptake of the radiolabelled glucose analog,
which has a similar metabolic route as glucose, via glucose
transporters (e.g., GLUT1) correlates with the metabolic
activity of the cell and therefore with the cells energy demand.
In the cell, the hexokinase phosphorylates 18F-FDG into 18F-
FDG-6-phosphate. Because of the inability of the glucose-
fructose isomerase to transduce phosphorylated 18F-FDG, it
is metabolically trapped in cells displaying high metabolism
and allowing visualization of 18F-FDG-biodistribution [15].
While the technique remained constant, the detection proce-
dure was refined with PET. By now, assessment of metabolic
activity via evaluation of glucose metabolism depicts a clini-
cally well-established method.
It has to be noted that 18F-FDG uptake is not a specific
event,meaning that no specificity for a disease or target exists.
Its uptake is related to tissue metabolism and presence of
glucose transporters. Since stimulated inflammatory cells as
well as tumor cells are metabolically very active and show an
increased expression of glucose transporters, 18F-FDG can be
deployed to reveal sites of inflammation and tumors.
Furthermore, the glucose transporters exhibit an elevated
affinity for deoxyglucose in an ongoing inflammatory state. In
fact, 18F-FDG has been successfully applied for clinical and
preclinical diagnosis in many pathologic settings like cancer
[15–18], inflammatory diseases such as atherosclerosis [19–
21], arterial inflammation [22], psoriasis [23], transplantation
medicine [24–28], asthma [29, 30], and fibrosis [31].
Kidney transplantation represents the therapy of choice
for patients suffering from end-stage renal failure. Despite
exceeding advances in transplantation medicine throughout
the last decades, allograft rejection still depicts a central issue
of graft failure. The leading cause of death-censored graft
loss is either humoral-mediated or T cell-mediated allograft
rejection. In this context, acute rejection (AR) episodes have
a great impact on the survival of the transplant. Since AR
correlates with the constraint of graft function, it is of major
importance to counteract its effect immediately. Therefore,
early detection of AR is essential. Different techniques to
address this aspect have been developed and until today
core-needle biopsy still constitutes the gold standard among
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these. However, considering the invasiveness of this method
it would be beneficial if noninvasive imaging methods were
clinically available which do not pose a risk for the grafts
integrity. We have demonstrated an interesting noninvasive
approach monitoring the uptake of 18F-FDG [27]. In PET,
visualisation of the transplant’s function as well as cellular
and molecular processes characteristic for AR like leuko-
cyte recruitment, restriction of renal activity, hypoxia, and
cell death is possible. Because of high metabolism due to
infiltration of inflammatory cells, a specific 18F-FDG-uptake
pattern arises, allowing determination of AR, while at the
same time discriminating fundamental differential diagnosis
in a rat renal allograft model [27].
In transplantation medicine, imaging of 18F-FDG uptake
has great potential to become a new method to accurately
determine and monitor rejection episodes (Figure 1) [27].
One fact concerning the clearance of 18F-FDG needs to be
taken into consideration. Elimination of 18F-FDG happens
via the urine causing drainage of the radiolabelled glucose
into the pelvis. This leads to a false positive signal which can
be significantly reduced by extending the time between tracer
application and tracer detection (late acquisition), ensuring
elimination of excessive tracer [27]. For clinical use, further
studies and careful assessment of risks for the patient need to
be performed.
As mentioned before, 18F-FDG uptake is a nonspecific
process. 18F-FDG is administered intravenously to monitor
biodistribution subsequently. A great amount of 18F-FDG
is needed in order to receive a clear signal of enhanced
metabolic activity since all cells exhibit metabolism to some
extent.
Because of the clinical importance of 18F-FDG as a
diagnostic tool, the development of inexpensive and readily
available glucose analogs applicable in SPECTwas supported.
99mTc-based glucose labelling was performed resulting in
the formation of glucose tracers failing to exhibit simi-
lar characteristics as 18F-FDG. Transport of these glucose
analogs into the cell was not mediated through GLUT1
nor did phosphorylation take place via hexokinase. Since
these features are essential for accumulation of the glucose
analogs in metabolic active cells, the 99mTc-labelled glu-
cose is not feasible for imaging of metabolism and fails to
substitute 18F-FDG. A reason for this could be a sterical
hindrance of the GLUT1 binding site through the 99mTc tag
[4].
4. Ex Vivo Labelling of Leukocytes
Inflammation is a process occurring in many distinctive
disease settings such as autoimmune diseases, infections, and
allograft rejection. During an ongoing inflammation, specific
cells including lymphocytes, granulocytes, and macrophages
are activated and recruited to the inflammatory site where
they infiltrate the affected tissue. Approaches to visualise
these infiltrating cells and therefore to image inflammation
have been performed via radiolabelled white blood cells
(WBC) and it has been shown that autologous leukocytes
radiolabelled with either 99mTc-HMPAO or 111In-oxine for
SPECT or 18F-FDG or 64Cu for PET, respectively, specifically
are enriched in inflamed tissues [32–34]. In fact, this is
an established clinical procedure used in many different
pathologic settings such as Crohn’s disease [35], osteomyeli-
tis [36], fever of unknown origin, infection [37], acute
appendicitis [38], and arterial and colonic inflammation
[39].
For successful imaging of radiolabelled cells a few aspects
need to be taken into account. First, regarding the applied
cells, it is notable that, before entering the reticuloendothelial
system consisting of spleen, liver, and bone marrow and
centre of acute and chronic inflammation through the blood
pool, the administered labelled WBC accumulate briefly in
the lung. Second, while the biodistribution of the radioactiv-
ity in normal human subjects forms a similar pattern inde-
pendent of the radionuclide (18F-FDG, 111In, and 99mTc) used
[40], the labelling stability varies. This aspect is important
to ensure that the captured radioactive signal reflects WBC
accumulation and that signal artefacts due to free (i.e., not
cell bound) tracers are eliminated.Third, compound stability
of the tracer and radionuclide half-life have to be taken into
account. 18F-labelling exhibits the lowest compound stability
and a radioactive half-life of 109min. Due to this short half-
life, long-time stability of this tracer is not of clinical interest.
For processes with a longer duration, other radionuclides
should be considered for labelling ( 99mTc-HMPAOhalf-life =
66 h).
Furthermore, labelling efficiency and viability of marked
cells reveal discrepancies when distinct radionuclides were
deployed. Labelling with 111In-oxine and 64Cu leads to
an approximate efficiency of 80% while the labelling rate
of 18F-FDG yields in 60% [41]. However, since labelling
of cytotoxic T cells reaches different efficiencies (111In-
oxine (68%), 18F-FDG (64%), and 99mTc-HMPAO (31%)),
labelling potential seems to be cell-type dependant [42].
Another important issue is viability of marked cells. Studies
have addressed this factor and demonstrated that similar
viability rates are reached with 111In-oxine-, 99mTc-HMPAO-
, 18F-FDG-, and 64Cu-labelling approaches in the first four
hours [41]. However, after a time period of 24 hours, a
sharp decline of cell survival was observed restricting long-
time monitoring of specific processes with a single-dose
application.
In preclinical and clinical studies labelled leukocytes were
utilized for detection of acute rejection in different organs
(intestine, heart, skin, or kidney). In kidney-transplanted
patients, scintigraphic analysis of 99mTc-labelled mononu-
clear cells allowed diagnosis of AR and discrimination from
acute tubular necrosis (ATN) [43]. In a more sophisticated
approach with PET, human leukocytes, in particular human
cytotoxic lymphocytes, marked with low amounts of 18F-
FDG ex vivo were applied in a rat kidney-transplant model
[44]. Subsequent PET analysis led to the differential diagnosis
of AR excluding other causes of early graft dysfunction
such as ischemia, ATN, or immunosuppressive toxicity
(Figure 2).
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Figure 1: A series of PET images of dynamicwhole-body acquisitions 180min after a single tail vein injection of 18F-FDG into an allogeneically
kidney-transplanted rat on postoperative day 4 (POD4). After development of acute rejection (the allograft shows an intense 18F-FDG
uptake on POD4) the recipient was treated with cyclosporine A showing already 24 h after commencement of immunosuppressive therapy
a significant decrease of the 18F-FDG uptake into the renal parenchyma (≜ therapy response). Please note that urine in the renal pelvis can
contain eliminated 18F-FDG. Therefore, it should be excluded from the assessments. Renal graft is marked with yellow circle. % ID: % of
injected dose. The figure was adapted from Reuter et al. [28].
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Figure 2: Exemplary PET images (day 4 after surgery) of dynamic whole-body acquisitions of allogeneically (aTX) and syngeneically
transplanted (sTX) rats, rats with ATN (IRI), and rats with acute cyclosporine toxicity (CSA). Effects are summarized after tail vein injection
of 18F-FDG—labeled T cells (maximum-intensity projection, whole-body acquisition for 20min at 60min (50–70min after injection). On
postoperative day 4 aTX kidneys exhibited significantly elevated 18F-FDG uptake in comparison to native controls. Accumulation of labelled
cells in kidneys with IRI or acute CSA toxicity and sTX was not significantly different from native controls. Please note that the renal pelvis
can contain eliminated 18F-FDG/18F-fluoride.Therefore, it has to be excluded from themeasurements. ID: injected dose.The figure was taken
from Grabner et al. [44].
5. In Vivo Labelling with Antibodies
Visualisation of inflammation without ex vivo labelled leuko-
cytes is possible via another approach utilizing radiolabelled
monoclonal antibodies (mAb) directed against infiltrating
cells. On first sight, many advantages are connected to this
procedure. On the one hand, a vast quantity of targeting
possibilities exists, allowing, at least theoretically, high speci-
ficity and a reasonable signal-to-noise ratio. On the other
hand, the procedure of antibody production is standardized
coming along with easy storage, simple administration, and
cost-effectiveness [2]. In spite of many advantages of this
method, some problems concerning target accessibility and
safety exist. Since the antibodies are not able to penetrate
tissues, targeting is restricted to intra- and perivascular
antigens, limiting their range of action. Furthermore, allergic
complications can arise when administering the antibodies
to a patient. Additionally, since antibodies are able to elicit
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an immune response, their immunogenicity needs to be
determined before their usage in order to prevent falsification
through their activity.
Numerous radiolabelled mAb and mAb fragments have
been designed to address infiltrating cells. Since T cells
and B cells constitute cell types playing a major role dur-
ing inflammation, antibodies directed against CD3, CD4,
CD8, CD25, CD20, and granulocytes have been devel-
oped. They are mainly marked with 99mTc, 111In, and 123I
[2].
In transplantation medicine a few approaches have
been performed to elucidate rejection episodes. Antibodies
directed against the CD3 complex, expressed on T cells,
natural killer cells (NK), and natural killer T cells (NK T),
have been designed to illustrate T-cell infiltration and thus
to determine AR. In a preliminary study, Martins et al.
applied 99mTc-OKT3 to successfully diagnose AR in kidney-
transplanted patients [45]; however, more data is needed to
confirm this finding. A clear disadvantage of this antibody
is a side effect due to immunogenicity. A more biocom-
patible humanized alternative but still in need of further
evaluation is the radiolabelled CD3 antibody 99mTc-SHNH-
visilizumab.
A vast number of possibilities exist to image targets
of interest accessible via the vascular system. In order to
deploy them for diagnosis of different diseases, identification
of specific markers upregulated during distinct pathologic
processes is necessary. Antibodies directed against vascular
proteins such as vascular adhesion molecule-1 (VCAM-
1), intercellular adhesion molecule-1 (ICAM-1), or selectins
could be used to address vascular-related diseases such as
atherosclerosis and visualise the sites of thrombus formation.
The greatest problem that needs to be overcome in this
setting is the clearance of unbound radiolabelled antibody
in order to improve the background-to-noise ratio. Since
free tracer circulates in the vascular system, producing a
SPECT or PET signal, the signal arising from the bound
antibody might be masked depending on the ratio of free-
to-bound antibody. Moreover, the high molecular weight of
most mAb constitutes a limitation since sequestration by
specific cellsmight result in diminution of available, freemAb
able to bind to the target of interest. On the contrary, mAb
tracers with low molecular weight might produce unspecific
signals due to their passive diffusion into and enrichment in
inflamed tissues. A possible solution of this problem could
be the selection of radiolabelled antibody fragments with
intermediatemolecular weight (40–80 kDa).These have been
demonstrated to exhibit features ideal for PET and SPECT
tracers such as low immunogenicity, fast blood clearance,
better enrichment in sites of inflammation, and no unspecific
binding to Fc receptors due to the absence of the Fc part [2].
6. Conclusion
Specific noninvasive methods for diagnosis of AR in trans-
plant patients are highly in demand. Molecular and cellular
imaging strategies using SPECT- or PET-based approaches
have great potential to fulfil these requests of allograft surveil-
lance. Advances in technology and tracer development open
new possibilities in regard to diagnosis and management
of renal rejection. Currently, nearly all of these promising
new approaches are still at an experimental stage. Future
studies will elucidate whether these diagnostics tools are
transmissible to transplant patients in clinical routine.
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